Regulus Therapeutics Inc. said director Mark Foletta will retire from the board upon the expiration of his current term ending at the 2018 annual meeting of stockholders.
The San Diego, Calif.-based company said Foletta's decision was a result of his concurrent service as the executive vice president and CFO for cancer drug developer Tocagen Inc.